3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
2
Myocardial Reperfusion Injury
2
Cardiotoxicity
2
Vomiting
1
Uveal Melanoma
1
Thrombosis
1
Retinal Diseases
1
Reperfusion Injury
1
Pain, Postoperative
1
Nausea
1
Melanoma
1
Macular Degeneration
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Choroid Diseases
1
Breast Neoplasms
1
Interventions
Sunitinib
26
Everolimus
20
Bevacizumab
19
aldesleukin
18
Sorafenib
16
Nivolumab
16
Interleukin-2
14
pembrolizumab
13
Peripheral Blood Stem Cell Transplantation
13
fludarabine phosphate
12
Radiotherapy
12
Interferon-alpha
12
Cyclophosphamide
12
Radiosurgery
11
Filgrastim
11
Blood Specimen Collection
11
Ipilimumab
10
Gemcitabine
10
Axitinib
9
Surveys and Questionnaires
7
Gene Expression Profiling
7
Cryosurgery
7
temsirolimus
6
pazopanib
6
Surgical Procedures, Operative
6
durvalumab
5
cabozantinib
5
atezolizumab
5
Mycophenolic Acid
5
Immunohistochemistry
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Kidney Neoplasms
×
salicylhydroxamic acid
×
Clear all
NCT04085237
2026-06-04
ESPB
McMaster University
Phase NA
Terminated
10 enrolled